MX2024004503A - Compuestos heteroarilo biciclicos fusionados utiles como inhibidores de proteina 3 que contiene dominios de pirina (nlrp3). - Google Patents
Compuestos heteroarilo biciclicos fusionados utiles como inhibidores de proteina 3 que contiene dominios de pirina (nlrp3).Info
- Publication number
- MX2024004503A MX2024004503A MX2024004503A MX2024004503A MX2024004503A MX 2024004503 A MX2024004503 A MX 2024004503A MX 2024004503 A MX2024004503 A MX 2024004503A MX 2024004503 A MX2024004503 A MX 2024004503A MX 2024004503 A MX2024004503 A MX 2024004503A
- Authority
- MX
- Mexico
- Prior art keywords
- sup
- compounds useful
- bicyclic heteroaryl
- fused bicyclic
- heteroaryl compounds
- Prior art date
Links
- 239000003112 inhibitor Substances 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 3
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/485—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Pulmonology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Inorganic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP21203314 | 2021-10-19 | ||
| EP22174872 | 2022-05-23 | ||
| PCT/EP2022/078755 WO2023066825A1 (en) | 2021-10-19 | 2022-10-17 | Fused bicyclic heteroaryl compounds useful as nlrp3 inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2024004503A true MX2024004503A (es) | 2024-05-06 |
Family
ID=84359071
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2024004503A MX2024004503A (es) | 2021-10-19 | 2022-10-17 | Compuestos heteroarilo biciclicos fusionados utiles como inhibidores de proteina 3 que contiene dominios de pirina (nlrp3). |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US20240279237A1 (https=) |
| EP (1) | EP4419532A1 (https=) |
| JP (1) | JP2024539068A (https=) |
| KR (1) | KR20240088922A (https=) |
| AR (1) | AR127386A1 (https=) |
| AU (1) | AU2022369332A1 (https=) |
| CA (1) | CA3228369A1 (https=) |
| CL (1) | CL2024001106A1 (https=) |
| CO (1) | CO2024004552A2 (https=) |
| CR (1) | CR20240158A (https=) |
| IL (1) | IL310442A (https=) |
| MX (1) | MX2024004503A (https=) |
| PE (1) | PE20241176A1 (https=) |
| TW (1) | TW202330545A (https=) |
| WO (1) | WO2023066825A1 (https=) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11618751B1 (en) | 2022-03-25 | 2023-04-04 | Ventus Therapeutics U.S., Inc. | Pyrido-[3,4-d]pyridazine amine derivatives useful as NLRP3 derivatives |
| US11319319B1 (en) | 2021-04-07 | 2022-05-03 | Ventus Therapeutics U.S., Inc. | Compounds for inhibiting NLRP3 and uses thereof |
| CA3261365A1 (en) * | 2022-07-28 | 2024-02-01 | Ac Immune Sa | NEW COMPOUNDS |
| US12331048B2 (en) | 2022-10-31 | 2025-06-17 | Ventus Therapeutics U.S., Inc. | Pyrido-[3,4-d]pyridazine amine derivatives useful as NLRP3 inhibitors |
| EP4667468A1 (en) * | 2023-02-14 | 2025-12-24 | Shenzhen Zhongge Biological Technology Co., Ltd. | Compound for inhibiting nlrp3, preparation method, and use |
| AU2024258000A1 (en) | 2023-04-19 | 2025-08-14 | F. Hoffmann-La Roche Ag | Oxazolo[4,5-b]pyrazine and oxazolo[4,5-b]pyridine derivatives as nlrp3 inhibitors for the treatment of e.g. inflammatory diseases |
| WO2025067343A1 (zh) * | 2023-09-27 | 2025-04-03 | 纽欧申医药(上海)有限公司 | 并环化合物及其应用 |
| WO2025099241A1 (en) * | 2023-11-10 | 2025-05-15 | Evotec International Gmbh | Nlrp3 modulators |
| US20250195511A1 (en) * | 2023-12-14 | 2025-06-19 | Merck Sharp & Dohme Llc | Indazole derivatives useful as inhibitors of nod-like receptor protein 3 |
| TW202532066A (zh) * | 2023-12-14 | 2025-08-16 | 美商默沙東有限責任公司 | 作為nod樣受體蛋白3抑制劑之氮雜吲唑衍生物 |
| WO2025146160A1 (zh) * | 2024-01-05 | 2025-07-10 | 北京普祺医药科技股份有限公司 | 杂环化合物及其药物组合物 |
| WO2025153532A1 (en) | 2024-01-16 | 2025-07-24 | NodThera Limited | Nlrp3 inhibitors and glp-1 agonists combination therapies |
| WO2025172260A1 (en) * | 2024-02-12 | 2025-08-21 | Evotec International Gmbh | Nlrp3 modulators |
| WO2025172521A1 (en) * | 2024-02-15 | 2025-08-21 | Evotec International Gmbh | Nlrp3 modulators |
| WO2026054623A1 (ko) * | 2024-09-09 | 2026-03-12 | (주) 업테라 | 신규 nlrp3 억제제 화합물 |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102116166B1 (ko) * | 2017-09-20 | 2020-05-27 | 건국대학교 글로컬산학협력단 | Nlrp3 억제제 |
| EP3953360B1 (en) | 2019-04-09 | 2024-02-28 | F. Hoffmann-La Roche AG | Heterocyclic compounds as inhibitors of monoacylglycerol lipase (magl) |
-
2022
- 2022-10-17 CA CA3228369A patent/CA3228369A1/en active Pending
- 2022-10-17 KR KR1020247012834A patent/KR20240088922A/ko active Pending
- 2022-10-17 EP EP22803219.9A patent/EP4419532A1/en active Pending
- 2022-10-17 MX MX2024004503A patent/MX2024004503A/es unknown
- 2022-10-17 AU AU2022369332A patent/AU2022369332A1/en active Pending
- 2022-10-17 JP JP2024523187A patent/JP2024539068A/ja active Pending
- 2022-10-17 WO PCT/EP2022/078755 patent/WO2023066825A1/en not_active Ceased
- 2022-10-17 AR ARP220102819A patent/AR127386A1/es unknown
- 2022-10-17 IL IL310442A patent/IL310442A/en unknown
- 2022-10-17 PE PE2024000806A patent/PE20241176A1/es unknown
- 2022-10-17 CR CR20240158A patent/CR20240158A/es unknown
- 2022-10-18 TW TW111139412A patent/TW202330545A/zh unknown
-
2024
- 2024-04-11 CL CL2024001106A patent/CL2024001106A1/es unknown
- 2024-04-11 CO CONC2024/0004552A patent/CO2024004552A2/es unknown
- 2024-04-17 US US18/637,966 patent/US20240279237A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CR20240158A (es) | 2024-05-22 |
| KR20240088922A (ko) | 2024-06-20 |
| WO2023066825A1 (en) | 2023-04-27 |
| CA3228369A1 (en) | 2023-04-27 |
| JP2024539068A (ja) | 2024-10-28 |
| AU2022369332A1 (en) | 2024-02-08 |
| EP4419532A1 (en) | 2024-08-28 |
| AR127386A1 (es) | 2024-01-17 |
| CO2024004552A2 (es) | 2024-04-29 |
| IL310442A (en) | 2024-03-01 |
| US20240279237A1 (en) | 2024-08-22 |
| TW202330545A (zh) | 2023-08-01 |
| PE20241176A1 (es) | 2024-05-28 |
| CL2024001106A1 (es) | 2024-10-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CR20240158A (es) | Compuestos heteroarilo bicíclicos fusionados útiles como inhibidores de nlrp3 | |
| MX2023012907A (es) | Inhibidores de inflamasoma proteina 3 que contiene dominios de pirina (nlrp3). | |
| CR20230496A (es) | Compuestos heterocíclicos | |
| MX2025004959A (es) | Derivados de triazinona como inhibidores de inflamasoma de proteina 3 que contiene dominios de pirina (nlrp3) | |
| EP4474017A3 (en) | New heterocyclic compounds | |
| MX2020008894A (es) | Inhibidores de oxazin monoacilglicerol lipasa (magl). | |
| MY209340A (en) | Egfr inhibitor for the treatment of cancer | |
| ZA202005326B (en) | Heteroaryl compounds as type ii irak inhibitors and uses hereof | |
| MX2023002224A (es) | Compuestos heterociclicos. | |
| CY1114213T1 (el) | Μεθοδοι απομονωσης κρυσταλλικης μορφης ι της 5-αζακυτιδινης | |
| EA200401157A1 (ru) | N-аминоацетилпирролидин-2-карбонитрилы и их применение в качестве ингибиторов ddp-iv | |
| MX2023009045A (es) | Derivados novedosos de pirimidin-2-il sulfonamida. | |
| MX2023011014A (es) | Inhibidores de heteroarílo de la calicreína plasmática. | |
| PH12022550433A1 (en) | Heterocyclic compounds | |
| MX2023009379A (es) | Derivados de tetrahidroazepina biciclicos para el tratamiento del cancer. | |
| MX2025005972A (es) | Compuestos novedosos como moduladores de la inhibicion de la proteina 3 que contiene un dominio de pirina de la familia de receptores similares al dominio de oligomerizacion de union a nucleotidos (nlrp3) | |
| CR20220004A (es) | Nuevos compuestos heterocíclicos | |
| EP4643954A3 (en) | Novel heterocyclic amine derivative and pharmaceutical composition comprising same | |
| CL2024001481A1 (es) | Compuestos de heteroaril-urea novedosos como inhibidores de kv7.2 | |
| MX2025003568A (es) | Compuestos y composiciones útiles como inhibidores de las proteínas inhibidoras de la apoptosis (iap) | |
| MX2025001765A (es) | Derivados deuterados de pirimidin-2-il sulfonamida | |
| MX2025000822A (es) | Derivados novedosos de indol sulfonamida 7 sustituidos | |
| EA200600018A1 (ru) | Производные никотинамида, полезные в качестве ингибиторов фдэ4 | |
| MX2025015239A (es) | Derivados de triazina como inhibidores del inflamasoma de proteina 3 que contiene un dominio de pirina (nlrp3) | |
| MX2021002087A (es) | Derivados de heteroarilo biciclicos. |